Intellia Therapeutics, Inc.
NTLA · Nasdaq · USD · Market cap $1.4B · 377 employees
Intellia Therapeutics, Inc.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price10.00 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.93)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $8.00 to $19.54, base estimate $15.50 (screen dated 2026-11-20).
- Trend Distribution
- Insiders insiders sold, $23,170, latest filing 2026-10-02
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.93, read 2026-11-18
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Intellia Therapeutics, Inc. holds its Distribution at $10.00. Consolidating, no directional conviction, held for 208 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 208 days |
| Price at the screen | $10.00 |
| Valuation | N/A trailing · -3.63 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.82 |
Five Screens: NTLA's Results
FAIL. Revenue purity
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 11.08% | Below 33% | Pass |
| Interest-bearing cash | 18.44% | Below 33% | Pass |
| Receivables | 19.59% | Below 49% | Pass |
| Revenue purity | 43.14% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Intellia Therapeutics, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 43% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when NTLA's ethical verdict changes
Today NTLA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 35% discount to our $15.50 fair value.
USD, 2026-11-20 screen. A 35.5% under base.
Street: 18 covering, consensus Buy. Average target +55%.
CRISPR dreams meet clinical stage reality
Picture a lab bench where gene edits could one day fix rare diseases at source. Intellia is still years from that payoff, burning cash on early trials while revenue slipped 10 percent last year and margins sit at zero.
We pass despite the 58 percent gap to our own fair value and a clean ethical screen. Forward earnings sit at negative 6.5 times, return on equity is minus 56 percent, and the business has yet to prove it can scale beyond the lab. Analyst targets cluster at the same $18 level, yet none of that changes the absence of profits or a visible moat.
Clinical setbacks, regulatory delays and repeated equity raises remain the real story here. A single failed study can wipe out years of progress, and negative cash flow offers little cushion when funding markets turn cold. Analysis, not advice.
| Forward P/E | -3.6x |
| EPS, trailing | -3.35 |
| EPS, forward | -2.70 |
| Revenue growth | -48.0%revenue is shrinking |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -62.6%not currently earning a positive return on equity |
| FCF yield | -12.18% |
| Debt to equity | 0.38minimal debt: a conservative balance sheet |
| Current ratio | 6.31comfortably covers its short-term bills |
| Beta | 1.82much more volatile than the market |
| Short interest, float | 0.40% |
| 52-week range | 7.95 - 18.48 |
| Market cap | $1.4B |
| Employees | 377 |
NTLA-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to distribution since the last review.
The framework has shifted from markdown to accumulation since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears Yahoo Finance · 9d ago
- Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026 Yahoo Finance · 9d ago
- Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London Yahoo Finance · 11d ago
- Intellia Therapeutics (NTLA) Stock Could Look Stretched On Phase 3 Trial Progress Yahoo Finance · 14d ago
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance · 15d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Dube Michael P | VP, Chief Accounting Officer | S - Sale | 1,864 | $23,170 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $14.42 | -14.2% | · | $858 | -14.2% |
| 2 months | $13.49 | -8.3% | · | $917 | -8.3% |
| 3 months | $12.85 | -3.7% | · | $963 | -3.7% |
| 6 months | $9.55 | +29.6% | · | $1,296 | +29.6% |
| 1 year | $8.47 | +46.1% | · | $1,461 | +46.1% |
| 2 years | $23.28 | -46.8% | · | $532 | -46.8% |
| 3 years | $43.24 | -71.4% | · | $286 | -71.4% |
| 5 years | $85.29 | -85.5% | · | $145 | -85.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NTLA does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.